SCHEMBL25249934

SCHEMBL25249934

Clc1cnn(C2CCOC2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LRRK2 Q5S007 4/20 0.40
▸ JAK2 O60674 1/20 0.40
▸ NAMPT P43490 1/20 0.39
▸ ROCK1 Q13464 1/20 0.37
▸ MKNK1 Q9BUB5 1/20 0.36
▸ MKNK2 Q9HBH9 1/20 0.36
▸ HCRTR1 O43613 1/20 0.36
▸ HCRTR2 O43614 1/20 0.36
▸ NTRK1 P04629 1/20 0.36
▸ KCNJ5 P48544 1/20 0.35
▸ IRAK4 Q9NWZ3 2/20 0.34
▸ MPO P05164 1/20 0.34
▸ MET P08581 1/20 0.33
▸ CDK1 P06493 1/20 0.33
▸ CCNB1 P14635 1/20 0.33
▸ CCNE1 P24864 1/20 0.33
▸ CDK2 P24941 1/20 0.33
▸ MAP3K12 Q12852 1/20 0.33
▸ IDO1 P14902 1/20 0.33
▸ TDO2 P48775 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15254559 0.79 LRRK2 (0.40) LRRK2JAK2NAMPTROCK1MKNK1
SCHEMBL9990474 0.79 LRRK2 (0.40) LRRK2JAK2NAMPTROCK1MKNK1
SCHEMBL12803700 0.79 MPO (0.55) LRRK2JAK2NAMPTROCK1MKNK1
SCHEMBL6936943 0.79 LRRK2 (0.43) LRRK2JAK2NAMPTROCK1MKNK1
SCHEMBL1430179 0.79 LRRK2 (0.40) LRRK2JAK2NAMPTROCK1MKNK1
SCHEMBL38654472 0.79 LRRK2 (0.43) LRRK2JAK2NAMPTROCK1MKNK1
SCHEMBL14466257 0.79 LRRK2 (0.43) LRRK2JAK2NAMPTROCK1MKNK1
SCHEMBL12862723 0.79 MPO (0.55) LRRK2JAK2NAMPTROCK1MKNK1
SCHEMBL1703399 0.79 LRRK2 (0.40) LRRK2JAK2NAMPTROCK1MKNK1
SCHEMBL31313175 0.79 MPO (0.55) LRRK2JAK2NAMPTROCK1MKNK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219965-A1 NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS KSQ Therapeutics, Inc. 2023-07-13 — — US disclosed
US-20230219965-A1 NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS KSQ Therapeutics, Inc. 2023-07-13 — — US disclosed
US-20230219965-A1 NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS KSQ Therapeutics, Inc. 2023-07-13 — — US disclosed
EP-4161494-A1 NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS KSQ Therapeutics, Inc. (US) 2023-04-12 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219965-A1 NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS USP1, USP8, USP7 LRRK2 714/4885JAK2 2072/4885NAMPT 4225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback